Non–probe-based imaging of apoptosis: Blankenberg and Strauss continue their focus on cell death imaging, this time looking at existing nonradionuclide clinical modalities, including ultrasound, MR, and optical imaging.
PET/CT in LABC: Groheux and colleagues study the effectiveness and impact of 18F-FDG PET/CT on initial staging in locally advanced breast cancer, including patients with both noninflammatory and inflammatory disease.
Dynamic PET/CT in pancreatic cancer: Epelbaum and colleagues assess the role of a quantitative dynamic 18F-FDG PET/CT model in pancreatic cancer as a potential index of tumor aggressiveness and predictor of survival.
PET textural features as predictors: Cook and colleagues explore the question of whether textural features of non–small cell lung cancer tumoral uptake in 18F-FDG PET images are correlated with patient survival and response to chemoradiotherapy.
MTV and anal cancer outcomes: Bazan and colleagues evaluate the prognostic potential of metabolic tumor volumes derived from PET in patients treated with definitive chemoradiotherapy for anal cancer.
177Lu-DOTA-octreotate dosimetry: Sandström and colleagues describe the development of an individualized dosimetry protocol for bone marrow in 177Lu-octreotate therapy and a process for individualized absorbed kidney/bone marrow dose calculation to optimize therapy.
18F-FDOPA PET in neuroblastic tumors: Lu and colleagues assess the accuracy and potential role of 18F-FDOPA PET in patients with neuroblastic tumors and compare results with those from 18F-FDG PET and 123I-MIBG scintigraphy.
Misregistration and flow estimation: Rajaram and colleagues study the effects of misregistration of cardiac PET/CT data on quantification of myocardial blood flow in patients with normal blood flow.
Quantitative PET/CTCA accuracy: Danad and colleagues investigate the diagnostic accuracy of quantitative H215O PET/CT-based coronary angiography in patients with suspected coronary artery disease and compare results with those from PET- or CT-based data alone.
Propofol and 11C-PBR28 binding: Hines and colleagues analyze the effect in healthy volunteers of the anesthetic propofol on brain uptake of this PET radioligand targeting translocator protein and discuss implications for cognitively impaired patients requiring anesthesia for PET imaging.
PiB and florbetapir: Landau and colleagues compare 11C-Pittsburgh compound B and 18F-florbetapir amyloid-β PET imaging in cognitively normal older adults and patients with mild cognitive impairment and Alzheimer disease and describe methods for standardizing and correlating results with the 2 tracers.
Imaging synaptic acetylcholine: Esterlis and colleagues examine whether β2-nicotinic acetylcholine receptor binding of 123I-5-IA on SPECT is sensitive to increases in extracellular levels of acetylcholine in humans.
Quantitative SPECT: Bailey and Willowson provide an educational overview of evidence-based reports on quantitative SPECT imaging and potential clinical applications.
PET and primary brain tumors: Evans and colleagues apply an 89Zr-labeled derivative of transferrin in animal PET studies designed to provide a more detailed identification of multiple types of tumor tissue in the brain.
Multimodal imaging nanophosphor: Lee and colleagues describe synthesis and initial evaluation of a 124I-labeled nanoparticle with promise for combined PET/MR/optical imaging in tumor angiogenesis and cancer-specific diagnoses.
99mTc-peptide and treatment response: Song and colleagues determine the effectiveness of SAAC(99mTc)-PSBP-6, a small-molecular-weight peptide, in PET detection of apoptosis induced by chemotherapy and review the tracer’s potential as a substitute for 18F-FDG.
166Ho-MSNs for radionuclide therapy: Di Pasqua and colleagues explore the utility of mesoporous silica nanoparticles as a carrier material for the stable isotope 165Ho and its subsequent radionuclide, 166Ho, in therapy for ovarian cancer metastasis.
18F-FSPG PET in HCC: Baek and colleagues investigate the tumor detection rate of this PET tracer, which assesses specific cysteine/glutamate exchange transporter activity, in patients with hepatocellular carcinoma.
Folic acid–targeted radionuclide therapy: Müller and colleagues detail a strategy in which a DOTA–folate conjugate with an albumin-binding entity was developed to prolong circulation in the blood and potentially improve tumor-to-kidney ratios for radiotherapy.
Improving PET kinetic modeling: Alf and colleagues test the feasibility of input function measurement with an arteriovenous shunt and a coincidence counter in mice and compare the method with an image-derived input function.
Imaging imidazoline-I2 binding sites: Kealey and colleagues use 11C to radiolabel a promising ligand compound for PET imaging of I2 brain binding sites in vivo in mice.
PET in cell therapy after stroke: Miyamoto and colleagues determine whether 18F-FDG PET can serially monitor the beneficial effects of transplanted bone marrow stromal cells on cerebral glucose metabolism in rat brain after induced ischemic stroke.
18F-FLT PET and experimental RA: Fuchs and colleagues study the feasibility of measuring cell proliferation noninvasively in vivo in mice during different stages of experimental arthritis using 18F-FLT PET.
Elucidating renal 99mTc-DMSA uptake: Weyer and colleagues use megalin/cubilin–deficient mice produced by gene knockout to determine whether receptor-mediated endocytosis is responsible for renal uptake of 99mTc-DMSA.
ON THE COVER
Representative views of MR imaging, PET, and digital autoradiography highlight the exceptional avidity of 89Zr-transferrin for an orthotopic glioblastoma multiforme tumor.
See page 90.
- © 2013 by the Society of Nuclear Medicine and Molecular Imaging, Inc.